BioStock: Principal investigator on Idogen’s clinical study with IDO 8

Idogen recently announced that they have received approval from the Swedish Medical Products Agency for the clinical phase I/IIa study with IDO 8. The cell therapy is aimed at patients with severe haemophilia A who have developed antibodies to their substitution therapy with coagulation factor VIII. BioStock contacted Professor Jan Astermark, Principal Investigator in the clinical study, to find out more about the unmet medical need of these patients.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/principal-investigator-on-idogens-clinical-study-with-ido-8/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se